Search

Displaying results 7021 - 7030 of 10000 in total
  1. Drug

    Iclaprim

    go.drugbank.com/drugs/DB06358
    Investigational

    Categories: Trimethoprim and Derivatives, Sulfonamides and trimethoprim
  2. Drug

    Anthramycin

    go.drugbank.com/drugs/DB19555
    Experimental

    Anthramycin is a small molecule drug. The usage of the INN stem '-mycin' in the name indicates that Anthramycin is a antibiotic, produced by Streptomyces strain.

    Categories: Benzodiazepines and benzodiazepine derivatives
  3. Drug

    99mTc-14 F7 Mab

    go.drugbank.com/drugs/DB05867
    Experimental

    99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. … Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect after treatment with 99mTc 14F7 Mab.

  4. Drug

    PM02734

    go.drugbank.com/drugs/DB05158
    Investigational

    PM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.

    Categories: Amino Acids, Peptides, and Proteins
  5. Drug

    Reversin 121

    go.drugbank.com/drugs/DB14072
    Experimental

    Reversin 121 is a hydrophobic peptide chemosensitizer that can reverse P-glycoprotein-mediated multidrug resistance.

    Categories: Amino Acids, Peptides, and Proteins
  6. Drug

    Ferrimannitol ovalbumin

    go.drugbank.com/drugs/DB15824
    Investigational

    Ferrimannitol-ovalbumin (FMOA) is an adduct between ovalbumin and the complex Fe(III)-mannitol.

  7. Drug

    Nicotinamide riboside

    go.drugbank.com/drugs/DB14933
    ApprovedInvestigationalWithdrawn

    Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).

  8. Drug

    Chromic citrate

    go.drugbank.com/drugs/DB14526
    Experimental

  9. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  10. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).